IBM: Quantum Advantage Is Not a Race, but a Matter of Business Readiness
Quantum computing is often perceived as an abstract goal pursued by technology giants. However, a new report from the IBM Institute for Business Value titled "Journey to Quantum Advantage" radically shifts this paradigm. According to the document, true quantum advantage is not a single milestone for everyone, but the ability to solve specific business problems more accurately, faster, or cheaper than classical computers.
What Drives Business?
The study, based on interviews with representatives from the aerospace industry, finance, energy, and biomedicine, identified three main reasons why corporations invest in quantum: 60% seek solutions for complex business problems, 55% are preparing their computing strategy for future changes, and 54% aim to accelerate innovation. The key finding is that success depends not only on hardware power but also on application scenarios, the availability of skilled personnel, and strategic partnerships.
Major Barriers on the Path
The main obstacle to adopting quantum technologies remains a shortage of specialized skills (61%). This is followed by the immaturity of the technology itself (56%) and unclear timelines for the emergence of practical scenarios (46%). This indicates that the market is in a phase of active learning and experimentation, rather than mass adoption. Companies face not only technical limitations but also questions of return on investment and finding tasks where quantum methods will deliver measurable results.
Practical Cases
Examples from the report are illustrative. Boeing is focusing on quantum chemistry for aircraft design. Since 2022, Vanguard has been testing hybrid approaches to combat money laundering and optimize portfolios. E.ON and Bosch, facing the limitations of current "noisy" hardware, have adjusted their roadmaps toward long-term preparation. In biomedicine, Yonsei University and the Wellcome Sanger Institute are already using quantum processors to study genomes, which could reduce drug development time by 10-20%.
The Ecosystem Matters
IBM particularly emphasizes the role of partnerships: every second quantum-ready organization participates in alliances with businesses, governments, and universities. This confirms that the quantum revolution is a collective process. I assess the current stage of the market as a period of "quantum maturity," where companies are moving from hype to pragmatic analysis. Quantum advantage will not be an instant breakthrough for all industries, but those who invest now in competencies and partnerships will gain a tremendous competitive edge in the next 5-10 years.